glp-1 c elegans Somatic DIV-1 promotes GLP-1/Notch-mediated germ cell proliferation A toolkit of tagged glp-1

Young J, Kritzer M, Mischel N, Taekman J, Weiner R

These schedules often recommend initiating treatment with a very low dose and progressively increasing it, depending on the individuals tolerance to side effects

The findings add to growing evidence to support the meaningful health benefits of GLP-1 drugs beyond weight loss

adults (~32 million people) have taken GLP-1 medications ( [1] ), and roughly 4% of all Americans (~13 million) were on a GLP-1 drug in 2024 ( [2] )

Lillys eloralintide (amylin receptor agonist), providing a potential option for Lilly to defend against amylin analogues, including Novo Nordisks CagriSema, which combines dual amylin and calcitonin receptor agonist cagrilintide and semaglutide, or Zealands petrelintide (phase 2) Structure Therapeutics GSBR-1290 (GLP-1), small molecule, oral obesity therapy, seeking to substantiate its earlier, positive phase 2a data to deliver competitive weight loss, against both other oral therapies and marketed injectables, with acceptable tolerability (phase 2b) Crucially, a number of phase 3 readouts in 2025 for key AOM assets will set the stage for their launch in 2026, when the next wave of AOMs enter the market to re-shape the competitive landscape: Lillys orforglipron (GLP-1), one of the first oral AOMs to launch, possibly alongside oral semaglutide, and when it does, the first small molecule based therapy in the market

2 Earlier this week, Reuters also confirmed 3 that Noom would continue to sell the compounded semaglutide moving forward